FI963514A0 - Hepatiitti A-viruksen viljelymenetelmä - Google Patents

Hepatiitti A-viruksen viljelymenetelmä

Info

Publication number
FI963514A0
FI963514A0 FI963514A FI963514A FI963514A0 FI 963514 A0 FI963514 A0 FI 963514A0 FI 963514 A FI963514 A FI 963514A FI 963514 A FI963514 A FI 963514A FI 963514 A0 FI963514 A0 FI 963514A0
Authority
FI
Finland
Prior art keywords
hepatitis
virus
cultivation process
cultivation
Prior art date
Application number
FI963514A
Other languages
English (en)
Swedish (sv)
Other versions
FI963514A (fi
Inventor
Frank S Leu
Douglas B Seifert
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of FI963514A0 publication Critical patent/FI963514A0/fi
Publication of FI963514A publication Critical patent/FI963514A/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165—Mumps or measles virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25—Varicella-zoster virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0068—General culture methods using substrates
    • C12N5/0075—General culture methods using substrates using microcarriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2531/00—Microcarriers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/10—Mineral substrates
    • C12N2533/12—Glass
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32451—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FI963514A 1994-03-08 1996-09-06 Hepatiitti A-viruksen viljelymenetelmä FI963514A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20816294A 1994-03-08 1994-03-08
PCT/US1995/002516 WO1995024468A1 (en) 1994-03-08 1995-03-03 Hepatitis a virus culture process

Publications (2)

Publication Number Publication Date
FI963514A0 true FI963514A0 (fi) 1996-09-06
FI963514A FI963514A (fi) 1996-11-06

Family

ID=22773456

Family Applications (1)

Application Number Title Priority Date Filing Date
FI963514A FI963514A (fi) 1994-03-08 1996-09-06 Hepatiitti A-viruksen viljelymenetelmä

Country Status (10)

Country Link
US (1) US6194210B1 (fi)
CN (1) CN1147833A (fi)
AU (1) AU1973795A (fi)
BR (1) BR9507333A (fi)
CZ (1) CZ258996A3 (fi)
FI (1) FI963514A (fi)
HR (1) HRP950097A2 (fi)
RO (1) RO115176B1 (fi)
WO (1) WO1995024468A1 (fi)
YU (1) YU15795A (fi)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP950097A2 (en) 1994-03-08 1997-06-30 Merck & Co Inc Hepatitis a virus culture process
ATE348155T1 (de) 1996-11-20 2007-01-15 Introgen Therapeutics Inc Ein verbessertes verfahren zur produktion und reinigung von adenoviralen vektoren
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US6146891A (en) 1997-01-31 2000-11-14 Schering Corporation Methods for cultivating cells and propagating viruses
DE69835813T2 (de) * 1997-01-31 2007-09-13 Schering Corp. Verfahren zur kultivierung von zellen und zur vermehrung von viren
US6168944B1 (en) 1997-01-31 2001-01-02 Schering Corporation Methods for cultivating cells and propagating viruses
TW570803B (en) * 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
US5994134A (en) * 1998-05-04 1999-11-30 Canji, Inc. Viral production process
US6689600B1 (en) * 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
KR100537718B1 (ko) * 1999-01-29 2005-12-20 씨제이 주식회사 에이형 간염 바이러스 백신 항원의 제조방법
WO2001014517A1 (fr) * 1999-08-20 2001-03-01 Japan Science And Technology Corporation Procede et appareil de proliferation du virus de l'hepatite
NZ527525A (en) * 2001-03-16 2005-03-24 Oncolytics Biotech Inc Extraction of infectious virus which is suitable for clinical administration to mammals
DE10145568A1 (de) * 2001-09-14 2003-04-03 Knoell Hans Forschung Ev Verfahren zur Kultivierung und Analyse mikrobieller Einzelzellkulturen
US6855535B2 (en) 2001-12-10 2005-02-15 Baxter Healthcare S.A. Method of large scale production of Hepatitis A virus
DE60327069D1 (de) 2002-04-30 2009-05-20 Oncolytics Biotech Inc Verbesserte reinigungsmethode für viren
GB0304799D0 (en) 2003-03-03 2003-04-09 Glaxosmithkline Biolog Sa Novel method
DE102004049290A1 (de) 2004-10-09 2006-04-20 Bayer Healthcare Ag Verfahren zur Herstellung von Virusmaterial
US7901921B2 (en) 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods
AU2005305347A1 (en) 2004-11-03 2006-05-18 Introgen Therapeutics Inc. Method of producing and purifying of adenoviral vectors
TWI627281B (zh) * 2009-09-02 2018-06-21 百靈佳殷格翰家畜藥品公司 降低ｐｃｖ－２組合物殺病毒活性之方法及具有改良免疫原性之ｐｃｖ－２組合物
RS53373B (en) 2009-12-16 2014-10-31 Vivabiocell Spa CONTINUOUS CULTIVATION DEVICE
CN102000326B (zh) * 2010-11-25 2013-10-16 成都康华生物制品有限公司 一种生产人用狂犬疫苗的方法
CN102058882B (zh) * 2010-12-28 2012-12-26 深圳康泰生物制品股份有限公司 一种制备甲型肝炎灭活疫苗的方法
CN103370077B (zh) * 2011-02-17 2016-10-26 贝林格尔.英格海姆维特梅迪卡有限公司 猪繁殖与呼吸综合征病毒的商业化规模生产方法
CN102492659A (zh) * 2011-11-14 2012-06-13 成都康华生物制品有限公司 一种疫苗生产用甲肝病毒的生产方法
WO2014150822A2 (en) 2013-03-15 2014-09-25 Boehringer Ingelheim Vetmedica, Inc. Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use
JP6783143B2 (ja) 2014-03-25 2020-11-11 テルモ ビーシーティー、インコーポレーテッド 培地の受動的補充
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
US11965175B2 (en) 2016-05-25 2024-04-23 Terumo Bct, Inc. Cell expansion
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
CN106754651B (zh) * 2017-02-28 2020-05-12 浙江普康生物技术股份有限公司 一种人二倍体细胞微载体培养有效传代的方法
JP7393945B2 (ja) 2017-03-31 2023-12-07 テルモ ビーシーティー、インコーポレーテッド 細胞増殖

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3105011A (en) 1961-06-19 1963-09-24 Parke Davis & Co Antigens and process of producing same
US3976547A (en) 1972-01-24 1976-08-24 Merck & Co., Inc. Cell and vaccine production
US3994870A (en) 1974-01-31 1976-11-30 The Community Blood Council Of Greater New York, Inc. Purification of hepatitis B surface antigen
US4031203A (en) 1974-12-09 1977-06-21 Merck & Co., Inc. Hepatitis A antigen
US4029764A (en) 1974-12-09 1977-06-14 Merck & Co., Inc. Hepatitis A antigen
US4017601A (en) 1975-10-16 1977-04-12 Merck & Co., Inc. Hepatitis A antigen
FR2398504A1 (fr) 1977-07-29 1979-02-23 Tours Inst Virologie Culture de virus de l'hepatite a, in vitro. application a la production d'un antigene reactif, d'immunserums specifiques et de vaccins contre l'hepatite a
US4296204A (en) 1978-01-25 1981-10-20 Merck & Co., Inc. Use of motionless mixer as cell culture propagator
DE2829741A1 (de) 1978-07-06 1980-01-24 Behringwerke Ag Verfahren zur gewinnung des hepatitis a-virus
US4164566A (en) 1978-08-17 1979-08-14 Merck & Co., Inc. Hepatitis a virus cell culture in vitro
JPS55147227A (en) * 1979-05-04 1980-11-17 Handai Biseibutsubiyou Kenkyukai Preparrtion of attenuated live mumps vaccine
US5021348A (en) 1979-09-04 1991-06-04 Merck & Co., Inc. Attenuated hepatitis A virus
CA1164799A (en) 1979-09-04 1984-04-03 Paula A. Giesa Cell culture of hepatitis a virus
US4415670A (en) 1980-07-07 1983-11-15 Merck & Co., Inc. Motionless mixer as cell culture propagator
US4301249A (en) 1980-07-23 1981-11-17 Merck & Co., Inc. High titer production of hepatitis A virus
DE3135599A1 (de) 1981-09-09 1983-08-25 Flehmig Bertram An menschliche fibroblastenzellen adaptierte hepatitis-a-viren
US4721675A (en) * 1982-02-01 1988-01-26 Abbott Laboratories Production of hepatitis A virus in vitro utilizing a persistently virus infected cell culture system
US4412002A (en) 1982-02-26 1983-10-25 Merck & Co., Inc. Process for preparing hepatitis A virus
US4448884A (en) * 1982-03-03 1984-05-15 Kms Fusion, Inc. Glass-surface microcarrier for growth of cell cultures
US4594339A (en) * 1982-04-06 1986-06-10 Sloan-Kettering Institute For Cancer Research Anti-herpes virus compositions containing 5-substituted 1-2'(deoxy-2-'-substituted-β-d-arabinofuranosyl)pyrimedene nucleosides
US4532215A (en) 1982-04-07 1985-07-30 The United States Of America As Represented By The Department Of Health And Human Services Isolation of hepatitis A virus strain HM-175
US4894228A (en) 1982-04-07 1990-01-16 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against hepatitis A virus
US4620978A (en) 1982-04-07 1986-11-04 The United States Of America As Represented By The Department Of Health And Human Services Hepatitis A virus purified and triply cloned
US4636469A (en) 1982-04-07 1987-01-13 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Isolation of hepatitis A virus strain HM-175
US4605623A (en) 1982-11-08 1986-08-12 Malette William Graham Method of altering growth and development and suppressing contamination microorganisms in cell or tissue culture
DE3484244D1 (de) 1983-09-30 1991-04-11 Massachusetts Inst Technology Herstellung von cdna die hepatitis a virale sequenzen darstellen.
US4614793A (en) 1983-10-14 1986-09-30 Merck & Co., Inc. Hepatitis A--subunit antigen
US4564532A (en) * 1985-01-07 1986-01-14 Kms Fusion, Inc. Glass-surface microcarrier for anchorage-dependent cell cultivation
US4636385A (en) * 1985-02-15 1987-01-13 The Wistar Institute Of Anatomy & Biology Vaccine, method for its preparation, and use thereof in vaccinating humans against rotavirus infection
US4683294A (en) 1985-04-03 1987-07-28 Smith Kline Rit, S.A. Process for the extraction and purification of proteins from culture media producing them
CA1324094C (en) 1985-04-03 1993-11-09 Dino Dina Hepatitis a virus vaccines
US4783407A (en) 1985-09-30 1988-11-08 Merck & Co., Inc. Growth of hepatitus A virus in vero cells
US4963489A (en) 1987-04-14 1990-10-16 Marrow-Tech, Inc. Three-dimensional cell and tissue culture system
US5160490A (en) 1986-04-18 1992-11-03 Marrow-Tech Incorporated Three-dimensional cell and tissue culture apparatus
SU1469856A1 (ru) 1986-07-31 1990-09-30 Институт биоорганической химии им.М.М.Шемякина Способ конструировани рекомбинантной плазмидной ДНК, кодирующей синтез полипептидных субстанций против гепатита А
US4975377A (en) 1987-05-14 1990-12-04 Key Marc E Cell growth chambers and method of use thereof
HUT48505A (en) 1987-06-29 1989-06-28 Attila Zsiger Wood-working-industrial auger drill
NZ225583A (en) 1987-08-06 1991-07-26 Merck & Co Inc Process for purifying hepatitis a virions (hav)
US5004688A (en) 1988-04-15 1991-04-02 Phillips Petroleum Company Purification of hepatitis proteins
JPH085804B2 (ja) 1988-04-28 1996-01-24 財団法人化学及血清療法研究所 Ａ型及びｂ型肝炎混合アジュバントワクチン
JPH0761955B2 (ja) 1988-04-28 1995-07-05 国立予防衛生研究所長 凍結乾燥ａ型肝炎ワクチン
JPH0751513B2 (ja) 1988-04-28 1995-06-05 国立予防衛生研究所長 Ａ型肝炎ワクチン
US5268292A (en) 1988-06-27 1993-12-07 Robertson Betty H Reproducible generation of high yields of hepatitis A virus by cell culture
CN1022331C (zh) 1989-08-17 1993-10-06 浙江省医学科学院 甲型肝炎减毒活疫苗毒种及其制造方法
CA2047041A1 (en) 1990-07-18 1992-01-19 John A. Lewis Process for purification of hepatitis-a virus capsids
DZ1706A1 (fr) * 1992-08-07 2002-02-17 Merck & Co Inc Vaccin contre le virus de l'hepatite a.
AU687012B2 (en) 1992-09-18 1998-02-19 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Hepatitis A virus vaccines
HRP950097A2 (en) 1994-03-08 1997-06-30 Merck & Co Inc Hepatitis a virus culture process

Also Published As

Publication number Publication date
YU15795A (sh) 1997-08-22
CZ258996A3 (en) 1997-06-11
RO115176B1 (ro) 1999-11-30
US6194210B1 (en) 2001-02-27
CN1147833A (zh) 1997-04-16
WO1995024468A1 (en) 1995-09-14
FI963514A (fi) 1996-11-06
BR9507333A (pt) 1997-09-16
AU1973795A (en) 1995-09-25
HRP950097A2 (en) 1997-06-30

Similar Documents

Publication Publication Date Title
FI963514A (fi) Hepatiitti A-viruksen viljelymenetelmä
DK0810877T3 (da) Hepatitis B-vaccine
NO976060D0 (no) Vaksiner mot hepatitt C
FI955445A0 (fi) Hajoavien polymeerien valmistusprosessi
IL132134A0 (en) Method for inactivating a virus
IT9019354A1 (it) Siringa a perdere
FI950567A0 (fi) Hepatitis A-virusrokote
FI972720A0 (fi) Menetelmä lamotrigiinin valmistamiseksi
BR9406711A (pt) Plantas resistentes a virus
EP0754243A4 (en) METHOD FOR DIAGNOSING CHRONIC HEPATITIS B VIRUS INFECTION
AU7679491A (en) Hepatitis c virus protease inhibitors
MD254B1 (ro) Procedeu de cultivare a marului
FI97937C (fi) Ulosvedin telekommunikaatiolaitekehikkoa varten
FI944460A0 (fi) Menetelmä lääkepreparaatin valmistamiseksi
FI943660A (fi) Menetelmä 3-karbonyyliandrostadieeni-17-karboksamidien valmistamiseksi
BR9506962A (pt) Cultura seletiva de virus
MD175F1 (ro) Procedeu de preparare a compostului
IL109650A0 (en) An animal model for hepatitis virus infection
SE9402342L (sv) För en CD-skiva anpassad konvolut
MD137F1 (ro) Procedeu de preparare a nutretului
IL106609A0 (en) Hepatitis a virus vaccine
HU0400424D0 (en) Hepatitis virus vaccines
LT2570B (lt) Stambiu raguociu leukozes viruso kultivavimo budas
FI945728A (fi) Shiitakesienien kasvatusvälineet
FI914307A0 (fi) Menetelmä keittomallin käyttämiseksi